Healium Medical
Yokneam, Israel· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $5M
Overview
Healium offers contact‑free ultrasound catheter ablation for atrial fibrillation and renal denervation, leveraging real‑time imaging and automated power control.
CardiovascularElectrophysiology
Technology Platform
Dual‑Mode Ultrasound Technology (DMUT) integrates intravascular imaging with therapeutic ultrasound to enable non‑contact, real‑time lesion creation and automated power titration based on tissue thickness.
Opportunities
Healium can capture a growing share of the $58 B cardiac ablation market by offering a contact‑free, image‑guided solution that reduces procedure time and repeat interventions, and by expanding into the emerging renal denervation space.
Risk Factors
Key risks include achieving regulatory clearance, demonstrating clinical superiority over established RF and cryo technologies, and securing reimbursement pathways in major markets.
Competitive Landscape
Main competitors are Medtronic, Abbott, and Boston Scientific, which dominate RF and cryo ablation; Healium differentiates through non‑contact ultrasound delivery and real‑time lesion monitoring.